Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsWith over a decade of experience in phage display technology, Creative Biolabs can provide a series of antibody or peptide libraries that are available for licensing or direct screening. These ready-to-use libraries are invaluable resources for isolating target-specific binders for various research, diagnostic or therapeutic applications. Highlights
Creative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
HighlightsWith deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
HighlightsGet a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
HighlightsThe solute carrier family 22 member 11 (SLC22A11) is a protein encoded by the SLC22A11 gene in humans. It is also known as Organic anion transporter 4 (OAT4). The SLC22A11 has an association with sodium-independent transport and excretion of organic anions, some of which are potentially toxic. The SLC22A11 is mainly expressed in the kidney and placenta, which prevents potentially harmful organic anions from reaching the fetus in the placenta. It is a complete membrane protein.
| Basic Information of SLC22A11 | |
| Protein Name | Solute carrier family 22 member 11 |
| Gene Name | SLC22A11 |
| Aliases | Organic anion transporter 4 (OAT4) |
| Organism | Homo sapiens (Human) |
| UniProt ID | Q9NSA0 |
| Transmembrane Times | 12 |
| Length (aa) | 550 |
| Sequence | MAFSKLLEQAGGVGLFQTLQVLTFILPCLMIPSQMLLENFSAAIPGHRCWTHMLDNGSAVSTNMTPKALLTISIPPGPNQGPHQCRRFRQPQWQLLDPNATATSWSEADTEPCVDGWVYDRSVFTSTIVAKWDLVCSSQGLKPLSQSIFMSGILVGSFIWGLLSYRFGRKPMLSWCCLQLAVAGTSTIFAPTFVIYCGLRFVAAFGMAGIFLSSLTLMVEWTTTSRRAVTMTVVGCAFSAGQAALGGLAFALRDWRTLQLAASVPFFAISLISWWLPESARWLIIKGKPDQALQELRKVARINGHKEAKNLTIEVLMSSVKEEVASAKEPRSVLDLFCVPVLRWRSCAMLVVNFSLLISYYGLVFDLQSLGRDIFLLQALFGAVDFLGRATTALLLSFLGRRTIQAGSQAMAGLAILANMLVPQDLQTLRVVFAVLGKGCFGISLTCLTIYKAELFPTPVRMTADGILHTVGRLGAMMGPLILMSRQALPLLPPLLYGVISIASSLVVLFFLPETQGLPLPDTIQDLESQKSTAAQGNRQEAVTVESTSL |
SLC22A11 is a solute carrier (SLC) family transporter that acts primarily as an organic/dicarboxylic acid exchanger. SLC22A11 is expressed on the basolateral membrane of the syncytia of the placenta and are assumed to be important for the removal of steroid sulfate from the fetal compartment, thereby promoting proper steroid signaling and minimizing toxic effects on developing fetuses. SLC22A11 and SLC22A12 (URAT1) encode a renal urate transporter located on chromosome 11. SLC22A11 is expressed on the apical membrane of renal proximal tubule cells. SLC22A12 is expressed across multiple tissue types and developmental stages, while expression of SLC22A11 is restricted to the kidney and placenta. The solute carrier (SLC) transporter (SLC22A11) is considered to be a model of transport which regulates a variety of abiotic and endogenous organic anions.
Fig.1 The structure of SLC22A11 Protein.
This analysis supports the fact that there are a number of specific effects on the SLC22A11/SLC22A12 locus that may affect the activity of SLC22A11 and URAT1 and the risk of gout.
The description of the genetic variation of resorbed transporters such as SLC22A11 is an important step in understanding changes in tubular resorption, which has an important impact on innate steady state processes and drug deployment.
These data suggest that 1,3-dicaffeoylquinic acid and 18β-glycyrrhetinic acid may lead to important hoat1-mediated DDIs in vivo. Safety issues should be considered in future drug development.
The authors propose that in the fetal blood circulation, glutamate reduces its transmembrane gradient and absorbs the placenta from the fetal circulation, while glutamate reuptake maintains this driving gradient.
The results reveal that the pharmacodynamic and in vitro activities of lesinurad are consistent with the inhibition of URAT1 and SLC22A11.
To obtain the soluble and functional target protein, the versatile Magic™ membrane protein production platform in Creative Biolabs enables many flexible options, from which you can always find a better match for your particular project. Aided by our versatile Magic™ anti-membrane protein antibody discovery platform, we also provide customized anti-SLC22A11 antibody development services.
Creative Biolabs' skillful scientists are glad to leverage our expertise and advanced technologies to help you with the member protein research. If you are interested, please feel free to contact us for more details.
All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.
